Merck Says FDA Grants Priority Review To Application For KEYTRUDA (pembrolizumab) Plus Padcev (enfortumab vedotin-ejfv) For First-Line Treatment Of Patients With Locally Advanced Or Metastatic Urothelial Cancer
Portfolio Pulse from Benzinga Newsdesk
Merck announced that the FDA has granted priority review to their application for KEYTRUDA in combination with Padcev for the first-line treatment of patients with locally advanced or metastatic urothelial cancer.
November 30, 2023 | 10:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Merck's KEYTRUDA, combined with Padcev, has been granted priority review by the FDA for treating advanced urothelial cancer, potentially enhancing Merck's oncology segment.
The FDA's priority review designation for KEYTRUDA in combination with Padcev is a positive development for Merck, indicating a significant advancement in its oncology pipeline. This could lead to increased investor confidence and a potential uptick in Merck's stock price in the short term as the market reacts to the news of a potentially enhanced product offering in a high-need medical area.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100